{"id":"atezolizumab-plus-tiraglolumab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Rash"},{"rate":"5-15%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking these interactions, Atezolizumab and Tiraglolumab aim to enhance the body's immune response against cancer cells. This is achieved by preventing the cancer cells from evading the immune system's attack. The combination of these two drugs may lead to a more effective anti-tumor response.","oneSentence":"Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:29.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors"}]},"trialDetails":[{"nctId":"NCT05661188","phase":"PHASE2","title":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","status":"RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2023-02-14","conditions":"Squamous Cell Carcinoma of the Anal Canal","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Atezolizumab plus Tiraglolumab","genericName":"Atezolizumab plus Tiraglolumab","companyName":"Grupo Espanol Multidisciplinario del Cancer Digestivo","companyId":"grupo-espanol-multidisciplinario-del-cancer-digestivo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 interaction, while Tiraglolumab is a TIGIT inhibitor that blocks the TIGIT/LAG-3 interaction, both of which are involved in immune checkpoint pathways. Used for Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}